4Tanaka M. Pharmacological and clinical profile of the free radical scavengerEdaravone as a neuroproteclive agent[J]. Nippon Yakurigaku Zasshi, 2002,119 (5) : 301-308.
4Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCJ-186), on acute brain infarction.Randomized, lacebo-controlled, double-blind study at multicenters.Cerebrovasc Dis, 2003, 15: 222 - 229.
5Takamatsu Y, Yuki S, Watanabe T. Studies on the concentration of 3 -methyl-1-1 phenyl-2-pyrazolin-5 -one (MCI-186) in MCA occlusion and reperfusion model of rats. Jpn Pharmacol Ther, 1997, 25(Suppl): S1785 - S1791.
6Jin YJ, Mima T, Raicu V, et al. Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils. Neurosci Res, 2002, 43:75 -79.
7Felberg RA, Burgin WS, Grotta JC. Neuroprotection and the ischemic cascade. CNS Spectrums, 2000, 5:52 -58.
8Takabatake Y, Uno E, Wakamatsu K, et al. The clinical effect of combination therapy with edaravone and sodium ozagrel for acute cerebral infarction. No To Shinkei, 2003, 55:589 -593.
9Tatsushi K, Yasuo K. Mild hypothermia enhances efficacy ofneuroprotective agents in cerebral ischemia in rats. International Congress Series, 2003, 1252:93 - 101.
10Charriaut-Marlangue C, Margaill I, Represa A, et al. Apoptosis and necrosis after reversible focal ischemia: an in situ DNA fragmentation analysis. J Cereb Blood Flow Metab, 1996, 16:186 - 194.
